oasis 1 oral semaglutide 50 mg obesity lancet 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial 🥼🧪Slide Deck: Efficacy and safety

Full-service Prescription Assistance Program devoted to helping uninsured Americans attain medications and prescriptions they need to live well

Eli Lillys oral GLP-1 candidate orforglipron met all primary and secondary endpoints in a Phase 3 study of adults with type 2 diabetes, the

It might feel like you just drank from a rusty pipe

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug use appears to be associated with increased residual gastric content (RGC) detected by gastric ultrasonography, a major risk factor for aspiration

GLP-1 therapies for weight loss & wellness | Semaglutide & more

Thomas Kruse and Sren stergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond.